Determining the Course of Medical Research – Second Nominee

Posted by Brigham and Women's Hospital October 17, 2013

Today’s video and Q&A features our second finalist in the 2013 Brigham and Women’s Hospital (BWH) BRIght Futures Prize competition, a research project from Daniel Solomon, MD, MPH, and Joel Weissman, PhD.

Power to the Patient (Video)

Daniel Solomon, MD, MPH, Division of Rheumatology
Joel Weissman, PhD, Center for Surgery and Public Health

What is your research project about?

Medical breakthroughs, such as vaccines, pacemakers, and X-rays, have changed the world. None of these advances could have happened without research.

Now, imagine that promising treatments could not be adequately tested because researchers were unable to recruit enough participants for clinical trials. This scenario is not so far-fetched. In fact, nearly 80 percent of clinical trials fail to recruit enough participants in time to meet enrollment deadlines. There are currently nearly 400 active clinical trials at BWH, and some researchers will likely end up stopping their studies due to recruitment difficulties.

Read More »

2013 BRIght Futures Prize: Promoting Innovative Medical Research

Posted by Brigham and Women's Hospital October 15, 2013

Dr. Robert C. Green, winner of the first BRIght Futures Prize.

Brigham and Women’s Hospital (BWH) is routinely recognized as one of the top academic medical centers in the country. Last year, the BWH Biomedical Research Institute launched the annual $100,000 BRIght Futures Prize competition to support innovative research that is both compelling and promising to an audience that extends beyond just scientists. The competition is intended to generate excitement and motivation within the research community, while heightening the visibility of BWH research worldwide. It supports researchers as they work to answer provocative questions and better meet today’s medical needs.

The three finalists were selected through a rigorous two-step peer review process, and the winner will be determined by public voting. The public is encouraged to vote for their favorite research project by visiting The winner will be announced during the awards ceremonies at the 2nd annual BWH Research Day on November 21. This event has the same goal of raising awareness and celebrating research at Brigham and Women’s Hospital. Registration is open not only to internal employees, but any individuals interested in learning more about the comprehensive science that goes on at the institution every day. Patients, local scientists, health care professionals, and industry collaborators all come together to interact with and learn more from BWH investigators and clinicians. Topics of focus this year include technology and innovation, personalized medicine, neuro-degeneration, and allergies, among others.

Read More »

New Developments in Treating Brain Tumors

Posted by Blog Administrator May 24, 2012

David A. Reardon

David Reardon: "Analysis of tumors means we can recommend clinical trials that offer patients the most promise and hope."

More than 600,000 people in the United States are living with a primary brain tumor – one that begins and stays in the brain – and over 60,000 adults and children will be diagnosed with a brain tumor this year. In recognition of May as Brain Tumor Awareness Month, we asked Dr. David Reardon, clinical director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’sCancerCenter, for the latest advances in brain tumor research and patient care.

Q. What are some of the challenges in treating brain tumors that you’re researching?

A.  For one thing, glioblastomas – the most common and aggressive primary brain tumors – are genetically very complex. The tumor cells are driven by multiple abnormal gene pathways, so we’re starting to use combinations of targeted drugs in “cocktails” that can block several pathways at once.

In addition, glioblastoma cells are adept at developing resistance to chemotherapy. We can now measure some enzymes whose levels predict which patients are more likely to develop resistance to a given drug.

Read More »